Anemia
Feature
In Ghana, SCD research is meeting patients on home turf
The West African nation stands ready to solve the geographic mismatch between research capacity and patient population.
News
Treatments, disease affect spermatogonia in boys
Alkylating agents, hydroxyurea (HU), and certain non-malignant diseases can significantly deplete spermatogonial cell counts in young boys,...
News
FDA approves biosimilar filgrastim
The US Food and Drug Administration (FDA) has approved the leukocyte growth factor Nivestym™ (filgrastim-aafi), a biosimilar to Neupogen (...
News
Kinase may be therapeutic target for hemoglobinopathies
A kinase called heme-regulated inhibitor (HRI) could be a therapeutic target for sickle cell disease (SCD) and some forms of β-thalassemia,...
From the Journals
Phase 3 results shed light on L-glutamine use in SCD
L-glutamine is not only an alternative to hydroxyurea but an additive therapy for patients with suboptimal response, the researchers said.
News
L-glutamine reduces complications of SCD
Results of a phase 3 trial showed that L-glutamine can reduce complications of sickle cell disease (SCD). SCD patients who received...
CME
CAR T Therapy: From Bench to Bedside and Back
News
A new use for ibrutinib?
Preclinical research suggests ibrutinib could treat G-CSFR-mutant myeloid disorders. “Mutations in G-CSFR have a harmful effect on the production...
Conference Coverage
Hydroxyurea well tolerated in longitudinal European study
WASHINGTON – Fewer than one in five adults experienced treatment-related adverse events and no secondary malignancies have been observed,...
News
FDA lifts hold on trial of MYC inhibitor
The US Food and Drug Administration (FDA) has lifted the clinical hold on a phase 1b trial of APTO-253. APTO-253 is a small molecule that...
Conference Coverage
Voxelotor cut transfusions in compassionate use sickle cell cohort
WASHINGTON – Hospitalizations and transfusions were down by about two-thirds in this severely affected group.